天弘国证生物医药ETF发起式联接A(011040)利润分配表
| |
2025-06-30 |
2024-12-31 |
2024-06-30 |
2023-12-31 |
| 收入 |
29,074,596.44 |
-281,085,403.20 |
-342,304,345.67 |
-237,030,114.99 |
| 利息合计 |
453,973.09 |
978,732.22 |
462,371.63 |
1,104,469.12 |
| 其中：存款利息收入 |
453,973.09 |
978,732.22 |
462,371.63 |
1,104,469.12 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-114,645,146.79 |
-93,755,813.15 |
-35,479,196.66 |
-120,890,374.33 |
| 其中：股票投资收益 |
-3,642,653.68 |
-19,554,648.93 |
-16,964,001.64 |
-6,215,971.54 |
| 基金投资收益 |
-111,148,487.33 |
-74,740,171.21 |
-19,019,323.17 |
-115,033,692.00 |
| 债券投资收益 |
1,560.62 |
38,809.89 |
17,885.07 |
6,982.62 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
144,433.60 |
500,197.10 |
486,243.08 |
352,306.59 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
143,146,990.91 |
-189,258,922.94 |
-307,428,366.52 |
-117,589,693.02 |
| 其他收入 |
118,779.23 |
950,600.67 |
140,845.88 |
345,483.24 |
| 费用 |
1,203,105.55 |
2,487,200.65 |
1,272,701.42 |
2,883,175.63 |
| 管理人报酬 |
183,372.57 |
418,523.76 |
237,370.40 |
483,840.35 |
| 基金托管费 |
36,674.51 |
83,704.73 |
47,474.10 |
96,768.08 |
| 销售服务费 |
892,310.50 |
1,801,972.16 |
888,403.02 |
2,102,567.20 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中：卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
90,747.97 |
183,000.00 |
99,453.90 |
200,000.00 |
| 利润总额 |
27,871,490.89 |
-283,572,603.85 |
-343,577,047.09 |
-239,913,290.62 |
微信公众号
证券之星APP
基本资料
